Filing Analysis
Rani Therapeutics Holdings, Inc. filed an 8-K to announce its corporate update and financial results for the three and six months ended June 30, 2026.
📋 Key Facts
- Report date: August 13, 2026
- Reporting period: Three and six months ended June 30, 2026
- The filing includes a press release (Exhibit 99.1) providing financial results and a corporate update.
- Company is an emerging growth company.
Rani Therapeutics Holdings, Inc. announced the appointment of Michelle Gilson to its Board of Directors and her designation as Chair of the Audit Committee, effective August 1, 2026.
📋 Key Facts
- Michelle Gilson appointed to the Board effective August 1, 2026.
- Ms. Gilson appointed as Chair of the Audit Committee.
- Former CFO of Arcellx, Inc. (acquired by Gilead Sciences in April 2026).
- Extensive background in biotech equity research and investment banking (Canaccord Genuity, Jefferies, Nomura, Goldman Sachs).
- Compensation to be provided under the Company’s Non-Employee Director Compensation Policy.
Rani Therapeutics Holdings, Inc. announced the appointment of Nicholas M. Maestas as Chief Financial Officer, effective June 29, 2026. He succeeds Svai Sanford, who is stepping down following the selection of his successor.
🚩 Red Flags
- Executive turnover (CFO departure), though framed as a planned succession.
📋 Key Facts
- Nicholas M. Maestas appointed CFO, principal financial officer, and principal accounting officer effective June 29, 2026.
- Svai Sanford to step down as CFO upon Maestas's commencement.
- Maestas's compensation includes a $500,000 annual base salary and a target annual bonus of 75% of base salary.
- Maestas granted 2,000,000 shares under the 2026 Equity Inducement Plan, vesting over four years (25% at year one).
- The Board approved the 2026 Equity Inducement Plan on June 28, 2026, reserving 5,500,000 shares for non-employee/director inducements.
Rani Therapeutics Holdings, Inc. reported the results of its annual meeting of stockholders held on May 28, 2026. All proposed matters, including the election of directors and the ratification of the independent auditor, were approved.
📋 Key Facts
- Annual Meeting held on May 28, 2026
- Record date for meeting was April 2, 2026
- Total voting shares: 99,812,515 Class A and 23,970,359 Class B common stock
- All seven director nominees (Talat Imran, Mir Imran, the others) were elected
- CBIZ CPAs P.C. was ratified as the independent registered public accounting firm for fiscal year 2026
Rani Therapeutics entered into a securities purchase agreement on May 26, 2026, to raise approximately $20.0 million in gross proceeds through the sale of 12,476,637 shares of Class A common stock and pre-funded warrants for 6,214,953 shares.
🚩 Red Flags
- Significant dilution to existing shareholders due to the issuance of over 18 million potential shares (common stock + warrants).
- Restrictive covenants preventing the issuance of new securities for 90 days and new variable rate transactions for nine months.
📋 Key Facts
- Offering price is $1.07 per share of Class A common stock and $1.0699 per pre-funded warrant.
- Aggregate gross proceeds expected to be approximately $20.0 million.
- Pre-funded warrants have an exercise price of $0.0001 per share and are exercisable immediately.
- Company has agreed not to issue further common stock or equivalents for 90 days, except as necessary for registration.
- Company will pay a cash fee of 6.0% of gross proceeds to placement agents H.C. Wainwright & Co., LLC and Chardan Capital Markets LLC.
- Directors, officers, and certain stockholders are subject to a 60-day lock-up period starting May 26, 2026.
Rani Therapeutics received a Nasdaq deficiency notice for failing to maintain a $1.00 minimum bid price and concurrently announced the resignation of its CFO, Svai Sanford. The company has until November 9, 2026, to regain compliance while searching for a new financial lead.
🚩 Red Flags
- Nasdaq minimum bid price deficiency notice
- CFO departure occurring simultaneously with listing non-compliance
- Multiple 8-K items (2.02, 3.01, 5.02) filed in a single report
- Mention of a potential reverse stock split to maintain listing
📋 Key Facts
- Received Nasdaq deficiency notice on May 11, 2026, due to the Class A common stock closing below $1.00 for 30 consecutive business days.
- CFO Svai Sanford resigned on May 12, 2026, but will remain in the role until a successor is appointed to ensure an orderly transition.
- Sanford's separation agreement includes 9 months of base salary ($491,400), 9 months of COBRA, and full acceleration of all unvested stock options and RSUs.
- The company has an initial 180-day period (ending November 9, 2026) to regain compliance by maintaining a $1.00 share price for 10 consecutive days.
- Management explicitly mentioned a reverse stock split as a potential remedy to cure the Nasdaq deficiency.
Rani Therapeutics Holdings, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The filing includes a press release with a corporate update and was signed by CFO Svai Sanford.
📋 Key Facts
- Financial results reported for the fourth quarter and full year ended December 31, 2025
- Press release issued and furnished on March 26, 2026
- Filing includes Item 2.02 (Results of Operations and Financial Condition)
- Exhibit 99.1 contains the full text of the earnings press release
Rani Therapeutics has undergone significant governance restructuring following a securities purchase agreement, including the termination of a Tax Receivable Agreement (TRA) with InCube Labs, LLC. The company implemented major changes to its charter that significantly reduce the voting power of Class B shares and limit stockholder rights.
🚩 Red Flags
- Significant reduction in dual-class voting power (Class B dilution of control).
- Elimination of stockholder rights to act by written consent and call special meetings.
- Implementation of supermajority voting requirements for fundamental corporate changes, which can entrench management/majority holders.
- Governance overhaul triggered by a private securities purchase agreement rather than a general shareholder vote.
📋 Key Facts
- Termination of Tax Receivable Agreement (TRA) with InCube Labs, LLC effective Dec 31, 2025; no termination payments required.
- Class B Common Stock voting power reduced from ten (10) votes per share to one (1) vote per share.
- Elimination of the ability for stockholders to act by written consent.
- Implemented a supermajority requirement (two-thirds of Class A and Class B voting power) to amend bylaws or the Restated Charter.
- Eliminated the ability of stockholders to call special meetings or fill board vacancies.
- The changes were approved via written consent by a 'Majority Holder' on November 24, 2025.
Rani Therapeutics Holdings, Inc. filed an 8-K to announce its corporate update and financial results for the three and nine months ended September 30, 2025.
📋 Key Facts
- Report date: November 6, 2025
- Reporting period: Three and nine months ended September 30, 2025
- The filing includes a press release (Exhibit 99.1) containing corporate updates and financial results.
- Company is an emerging growth company.
Rani Therapeutics Holdings, Inc. completed a significant private placement involving the issuance of over 42 million shares and substantial warrants. This capital raise triggered a reconstitution of the Board of Directors, including the resignation of two directors and the appointment of two new members tied to the investment firms participating in the offering.
🚩 Red Flags
- Significant dilution: The issuance of new shares and warrants represents a massive increase in potential share count relative to current outstanding shares.
- Board reconstitution tied to private placement: New directors are appointed as a condition/right of the investment, indicating investor-led governance changes.
- Potential for significant warrant overhang due to the large number of common and pre-funded warrants issued.
📋 Key Facts
- Closed a Private Placement on October 23, 2025.
- Issued 42,633,337 shares of Class A Common Stock.
- Issued warrants to purchase up to 125,000,004 shares of Class A Common Stock or pre-funded warrants.
- Issued pre-funded warrants to purchase up to 82,366,667 shares of Class A Common Stock.
- Post-closing total outstanding Class A Common Stock: 97,541,221 shares.
- Resignation of directors Andrew Farquharson and Maulik Nanavaty effective upon closing.
- Appointment of Abraham Bassan (Samsara BioCapital) and Vasudev Bailey, Ph.D. (Anomaly Ventures) to the Board.
- New board members hold rights to designate one member each if their respective firms own at least 25% of securities issued in the placement.
Rani Therapeutics announced a massive $60.3 million private placement involving significant equity dilution and a major collaboration agreement with Chugai Pharmaceutical. The filing also includes an amendment to convert $6.0 million of existing debt into equity.
🚩 Red Flags
- Massive potential dilution: The number of warrants (over 207 million total) significantly exceeds current outstanding common stock, which will heavily dilute existing shareholders upon exercise.
- Related-party transaction: Board member Mir Imran is participating in the private placement at a premium ($0.605 vs $0.48).
- Debt-to-equity conversion: Existing debt of $6M is being converted to equity, indicating potential liquidity pressure or restructuring needs.
- Warrant overhang: The scale of warrants could create significant downward selling pressure in the open market once they become exercisable.
📋 Key Facts
- Private placement of 42,633,337 shares at $0.48/share (Institutional) and $0.605/share (Affiliated Investor).
- Issuance of warrants to purchase up to 125,000,004 shares and pre-funded warrants for 82,366,667 shares.
- Expected gross proceeds of approximately $60.3 million before fees.
- Collaboration agreement with Chugai Pharmaceutical: $10M upfront, up to $175M in total milestones, plus royalties.
- $6.0 million debt conversion from Avenue Venture Opportunities Fund into 12,500,000 shares/warrants.
- Registration rights agreement filed to register the new securities within 15 days of closing.
Rani Therapeutics Holdings, Inc. filed an 8-K to provide a corporate update and announce financial results for the three and six months ended June 30, 2025.
📋 Key Facts
- Report date: August 7, 2025
- Reporting period: Three and six months ended June 30, 2025
- The filing includes a press release (Exhibit 99.1) containing corporate updates and financial results.
- The company is an emerging growth company.
Rani Therapeutics announced a $3.0 million private placement of Class A common stock and pre-funded warrants to an institutional investor at a significant discount to previous market context. Additionally, the company has suspended its existing At-The-Market (ATM) equity offering program.
🚩 Red Flags
- Significant dilution: Issuance of over 7 million total securities (including warrants) for a relatively small $3M raise.
- Low share price context: The offering price of $0.40 suggests potential liquidity/capital constraints typical of micro-cap biotech firms.
- Suspension of ATM: Suspending the existing ATM program while simultaneously conducting a discounted private placement may indicate a need to manage share price volatility or specific financing needs.
📋 Key Facts
- Offering size: 4,354,000 shares of Class A common stock and 3,146,000 pre-funded warrants.
- Pricing: $0.40 per share of common stock; $0.3999 per pre-funded warrant.
- Expected gross proceeds: Approximately $3.0 million (before fees).
- Closing date: Expected on or about July 16, 2025.
- Placement Agent: Maxim Group LLC (5.25% cash fee).
- Lock-up: Directors and officers are subject to a 45-day lock-up period following closing.
- ATM Suspension: Suspended use of the prospectus supplement for the H.C. Wainwright & Co., LLC Sales Agreement.
Rani Therapeutics Holdings, Inc. received a notice from Nasdaq stating it is in violation of the minimum bid price requirement ($1.00 per share). The company has been granted a 180-day grace period to regain compliance.
🚩 Red Flags
- Delisting notice from Nasdaq
- Failure to maintain minimum bid price requirement ($1.00)
- Potential for mandatory reverse stock split if compliance is not met via market appreciation
📋 Key Facts
- Nasdaq notified the company on June 20, 2025, regarding non-compliance with Nasdaq Listing Rule 5450(a)(1).
- The deficiency is due to the closing bid price being below $1.00 for the prior 30 consecutive business days.
- The company has a 180-day period to rectify the deficiency, ending on December 17, 2025.
- To regain compliance, the company must maintain a minimum bid price of at least $1.00 for 10 consecutive business days.
- If compliance is not met by Dec 17, 2025, the company may seek an additional 180-day extension by transferring to the Nasdaq Capital Market, which would likely require a reverse stock split.
Rani Therapeutics Holdings, Inc. reported the results of its annual meeting of stockholders held on May 28, 2025. Stockholders approved the election of seven directors and ratified the appointment of CBIZ CPAs P.C. as the independent auditor for fiscal year 2025.
📋 Key Facts
- Annual Meeting held on May 28, 2025.
- Seven director nominees (Talat Imran, Mir Imran, Dennis Ausiello, Jean-Luc Butel, Andrew Farquharson, Malik Nanavaty, and Lisa Rometty) were elected to hold office until the 2026 annual meeting.
- CBIZ CPAs P.C. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Record date for the meeting was April 2, 2025.
- Voting included both Class A (1 vote per share) and Class B (10 votes per share) common stock.
Rani Therapeutics entered into a letter agreement with an existing institutional investor to issue new Series D warrants and significantly down-round existing Series B and C warrants. The transaction involves massive dilution as exercise prices for previous warrants are slashed from ~$3.00 to $0.65 per share.
🚩 Red Flags
- Extreme dilution: Massive reduction in exercise prices (from ~$3.00 to $0.65) indicates a significant down-round.
- Warrant overhang: Issuance of over 13 million new warrants plus the exercise of existing ones will significantly increase share count.
- Related-party transaction: Net proceeds are being used to purchase LLC interests from Rani LLC, suggesting capital is flowing to an entity controlled by/related to the company.
- Potential liquidity crunch: The $4.3M gross proceeds appear small relative to the scale of dilution and warrant issuance.
📋 Key Facts
- Company to issue Series D common stock warrant for up to 13,160,172 shares at an exercise price of $0.65/share.
- Series B Warrant (3,246,753 shares) exercise price reduced from $3.08 to $0.65 per share; investor agreed to exercise in full.
- Series C Warrant (3,333,333 shares) exercise price reduced from $3.00 to $0.65 per share; investor agreed to exercise in full.
- Gross proceeds from Series B and C exercises estimated at approximately $4.3 million.
- Net proceeds will be used by the Company to purchase newly issued LLC Interests from Rani LLC for working capital.
- Maxim Group LLC acting as financial advisor with a 5.25% cash fee on gross proceeds.
Rani Therapeutics Holdings, Inc. filed an 8-K to announce its quarterly financial results and provide a corporate update for the period ending March 31, 2025.
📋 Key Facts
- The filing relates to the three months ended March 31, 2025.
- The company issued a press release (Exhibit 99.1) containing financial results and a corporate update.
- The report was signed by Svai Sanford, Chief Financial Officer, on May 13, 2025.
Rani Therapeutics Holdings, Inc. received a deficiency notice from Nasdaq regarding its failure to maintain the minimum Market Value of Listed Securities (MVLS) requirement. The company has been below the $50 million threshold for 30 consecutive business days.
🚩 Red Flags
- Delisting notice from Nasdaq
- Failure to meet minimum market value standards (MVLS)
- Risk of delisting if compliance is not met by October 28, 2025
📋 Key Facts
- Received Nasdaq Notice on May 1, 2025.
- Deficiency relates to Rule 5450(b)(2)(A) regarding Market Value of Listed Securities (MVLS).
- The company's MVLS has been below the $50,000,000 minimum for 30 consecutive business days.
- The company has a 180-day compliance period ending October 28, 2025.
- To regain compliance, the company must maintain an MVLS of at least $50,000,000 for 10 consecutive business days.
Laureen DeBuono has retired from the Board of Directors and her roles on the Audit and Compensation Committees, effective April 24, 2025. The company has reconstituted its board committees in response to this departure.
🚩 Red Flags
- None identified; departure is characterized as a standard retirement without disagreement.
📋 Key Facts
- Laureen DeBuono retired from the Board effective April 24, 2025.
- The departure was not due to any disagreement with the Company regarding operations, policies, or practices.
- Ms. DeBuono served on both the Audit Committee and Compensation Committee prior to retirement.
- The Board reconstituted the Audit, Compensation, Nominating/Governance committees following the resignation.
Rani Therapeutics Holdings, Inc. announced the resignation of its independent auditor, Marcum LLP, and the appointment of CBIZ CPAs P.C. as its new auditor effective April 7, 2025.
🚩 Red Flags
- Auditor change combined with existing 'going concern' language in recent financial statements.
- Presence of substantial doubt regarding the company's ability to continue as a going concern (as noted in the 2024 audit report).
📋 Key Facts
- Marcum LLP resigned as the independent registered public accounting firm on April 7, 2025.
- CBIZ CPAs P.C. was appointed by the Audit Committee to serve as the new auditor for the fiscal year ending December 31, 2025.
- The company's fiscal year 2024 audit report included an explanatory paragraph noting substantial doubt about the Company’s ability to continue as a going concern.
- Marcum stated there were no disagreements with the company regarding accounting principles or auditing procedures.
Rani Therapeutics Holdings, Inc. filed an 8-K to announce its fourth quarter and full year 2024 financial results and provide a corporate update via press release.
📋 Key Facts
- Report date: March 31, 2025
- Reporting period: Fourth quarter and year ended December 31, 2024
- The filing includes Exhibit 99.1 containing the full press release of financial results.
- Company is an emerging growth company.
Rani Therapeutics Holdings, Inc. filed an 8-K to announce its quarterly financial results and provide a corporate update for the period ending September 30, 2024.
📋 Key Facts
- Report date: November 14, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and corporate updates.
- Company is classified as an emerging growth company.
Rani Therapeutics entered into a securities purchase agreement on October 15, 2024, to raise approximately $10 million through the issuance of Class A common stock, pre-funded warrants, and Series C common warrants. The offering includes the cancellation of previously issued Series A common warrants.
🚩 Red Flags
- Dilutive structure: The inclusion of significant warrants (Series C) at $3.00 per share creates potential future dilution for existing shareholders.
- Warrant cancellation: The cancellation of Series A warrants in favor of this new structure suggests a restructuring of previous financing terms.
- Cash burn/Liquidity need: Raising $10M is relatively small for a biotech, suggesting ongoing capital requirements.
📋 Key Facts
- Total expected gross proceeds: ~$10.0 million (before fees).
- Issuance of 3,000,000 shares of Class A common stock.
- Issuance of pre-funded warrants to purchase 333,333 shares at $0.0001 per share.
- Issuance of Series C common warrants to purchase 3,333,333 shares with an exercise price of $3.00 per share (5-year term).
- Cancellation of previously issued Series A common warrants (3,246,753 shares) from July 23, 2024.
- Maxim Group LLC acting as placement agent with a 5.25% cash fee.
- Lock-up period for directors and officers for 30 days following closing.
Rani Therapeutics Holdings, Inc. has dismissed Ernst & Young LLP (EY) as its independent registered public accounting firm and appointed Marcum LLP as its new auditor effective September 10, 2024.
🚩 Red Flags
- Auditor change (EY to Marcum LLP) often warrants scrutiny in micro-cap/biotech sectors.
- Existing 'going concern' language in the FY2023 audit report remains a critical risk factor for the company's solvency.
📋 Key Facts
- Dismissal of EY approved by the Audit Committee on September 10, 2024.
- Appointment of Marcum LLP to serve for the fiscal year ending December 31, 2024.
- The FY2023 audit report from EY included an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern.
- No disagreements with EY on accounting principles, practices, or auditing procedures were reported for the periods ending Dec 31, 2022, Dec 31, 2023, or through Sept 10, 2024.
Rani Therapeutics Holdings, Inc. filed an 8-K to furnish a press release containing its corporate update and financial results for the quarter ended June 30, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly financial results (Q2 2024).
- Report date: August 6, 2024.
- Reporting period: Quarter ended June 30, 2024.
- The company is an emerging growth company.
Rani Therapeutics entered into a securities purchase agreement on July 22, 2024, to issue Class A common stock and various warrants to an institutional investor. The offering aims to raise approximately $10.0 million in gross proceeds.
🚩 Red Flags
- Significant dilution potential due to the large number of warrants (Series A and B) being issued alongside common stock.
- Lock-up period for directors and officers for 60 days following closing.
- The company is prohibited from issuing new variable rate transactions or other equity for a specified period post-closing.
📋 Key Facts
- Issuance of 2,800,000 shares of Class A common stock.
- Issuance of 446,753 pre-funded warrants (exercise price $0.0001).
- Issuance of Series A and Series B common warrants to purchase an aggregate of 6,493,506 shares at an exercise price of $3.08.
- Expected gross proceeds: approximately $10.0 million.
- Maxim Group LLC acting as placement agent with a 6.0% cash fee and up to $50,000 in expense reimbursement.
- Closing expected on or about July 23, 2024.
Rani Therapeutics announced it has decided not to proceed with a potential equity financing after engaging in discussions with various investors. The company cited its current cash position, business outlook, and market conditions as reasons for the decision.
🚩 Red Flags
- Implicit liquidity concern: The decision to evaluate 'cash needs' following failed/abandoned financing discussions suggests a focus on capital preservation.
- Market timing issues: The company noted 'market conditions' as a reason for not proceeding, suggesting difficulty in securing favorable terms.
📋 Key Facts
- The Company engaged in discussions with various investors regarding a potential equity financing.
- The Company has elected not to move forward with an equity financing at this time.
- Decision based on cash position, business outlook, and market conditions.
- Company may seek additional equity financing in the future.
Rani Therapeutics entered into a collaboration agreement with ProGen Co., Ltd. to develop and commercialize an oral delivery of the GLP-1/GLP-2 dual agonist PG-102 using Rani's RaniPill HC device for weight management.
🚩 Red Flags
- The 'Opt-Out' clause allows either party to exit the collaboration, which could lead to litigation or complex royalty/cost-sharing disputes if one party seeks to control the asset exclusively.
📋 Key Facts
- Agreement dated June 17, 2024, between Rani Therapeutics, LLC and ProGen Co., Ltd.
- Target product: Combination of ProGen’s PG-102 (GLP-1/GLP-2 dual agonist) and RaniPill HC oral delivery device.
- Indication: Weight management (obesity, weight reduction, and maintenance).
- Development split: Rani leads preclinical through Phase 1; after Phase 1 initiation, Rani leads in US, Canada, Europe, UK, and Australia; ProGen leads all other countries.
- Commercialization split: Exclusive rights to assigned territories for both parties.
- Cost/Profit sharing: Development costs and operating profits/losses are shared equally (50/50).
- Opt-out provision: Either party can opt-out, with the continuing party gaining sole rights subject to royalties and cost-sharing obligations.
Rani Therapeutics Holdings, Inc. held its annual meeting of stockholders on May 29, 2024. Stockholders approved the election of eight directors and ratified Ernst & Young, LLP as the independent auditor for the fiscal year ending December 31, 2024.
📋 Key Facts
- Annual Meeting held on May 29, 2024.
- Eight director nominees (Talat Imran, Mir Imran, Dennis Ausiello, Jean-Luc Butel, Laureen DeBuono, Andrew Farquharson, Malik Nanavaty, and Lisa Rometty) were elected to hold office until the 2025 annual meeting.
- Ernst & Young, LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Voting results showed overwhelming support for all director nominees and the auditor appointment.
Rani Therapeutics Holdings, Inc. issued an 8-K to announce its quarterly financial results and provide a corporate update for the three months ended March 31, 2024.
📋 Key Facts
- Report date: May 6, 2024
- Reporting period: Three months ended March 31, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and corporate updates.
- Company is classified as an emerging growth company.
Rani Therapeutics Holdings, Inc. filed an 8-K to announce its fourth quarter and full year 2023 financial results via a press release. The filing serves as a standard corporate update regarding the company's recent operational and financial performance.
📋 Key Facts
- Report date: March 20, 2024
- Reporting period: Fourth quarter and year ended December 31, 2023
- The filing includes a press release (Exhibit 99.1) detailing financial results.
- Company is classified as an 'Emerging Growth Company'.
Rani Therapeutics announced positive topline results from its Phase 1 clinical trial of RT-111, an oral RaniPill capsule containing a ustekinumab biosimilar. The study demonstrated that the oral delivery method was well-tolerated and achieved high bioavailability compared to subcutaneous injection.
🚩 Red Flags
- None identified in this clinical update.
📋 Key Facts
- Phase 1 study evaluated safety and tolerability of RT-111 (ustekinumab biosimilar) in healthy volunteers in Australia.
- Study included 55 participants: 20 at 0.5mg dose, 20 at 0.75mg dose, and 15 control subjects receiving subcutaneous STELARA®.
- RT-111 was generally well tolerated with no serious adverse events (SAEs) reported.
- Estimated bioavailability of 0.5mg RT-111 was 84% relative to the subcutaneous SC STELARA® injection.
- No participants reported difficulty swallowing the capsule; remnants passed without sequelae.